Insider Purchases: Inside the Buy

Tag: Biotech Innovation

DNA stock chart tug-of-war between shorts and insider buyers for Intellia (NTLA).

Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?

NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.

Read entire article

Tags: Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, biotech jokes, Biotech Picks, buy-or-sell-ntla, clinical-trials, CRISPR, CRISPR Gene Editing, death-in-trial, fda, fda-hold, featured-epiphany, featured-insiders, funstock-index, gene-editing, healthcare-stocks, high-risk-high-reward, hub-epiphany, hub-insiders, insider-buys, Intellia Therapeutics, nasdaq, Ntla, risks-buying-ntla, short-interest, speculative-stocks, spotlight-health, why-buy-ntla
Digital illustration of a DNA strand fusing with glowing AI circuitry inside a futuristic lab, symbolizing Absci’s generative AI drug discovery technology.

Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!

AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.

Read entire article

Tags: Absci, ABSI, ABSI Stock, AI, AI in Biotech, AI Stocks, Almirall, AMD, Ark Invest, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, Biotech Partnerships, Biotech Stocks, Buy ABSI Stock, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, Chief Innovation Officer Buying Shares, Director Insider Buying, drug discovery, FMR, Funanc1al, Funanc1al Edge, insider purchases, institutional ownership, investing humor, Oracle, Redmile Group, speculative stocks
A confident businesswoman holds a glowing blue DNA helix like a lightsaber, standing against a golden background with a rising stock chart and the Vertex Pharmaceuticals logo—symbolizing innovation, biotech strength, and market growth.

CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?

Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?

 

Read entire article

Tags: Biotech Innovation, Biotech Investing, Buy VRTX Stock, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Funanc1al, Funanc1al Edge, Funanc1al Investing, Gene editing, Growth at a reasonable price, Reshma Kewalramani, Type 1 diabetes cure, Vertex Pharmaceuticals, VRTX